Nestlé has launched a plant-based drink for toddlers named Little Steps Plantygrow, which can be added to smoothies and shakes.
The company emphasized that the plant-based 'Growing Up Drink,' marketed under its SMA Nutrition range, is not a breast milk substitute, but a nutritional product designed to be enjoyed by toddlers from 1 to 3 years old as part of a varied and balanced diet.
According to Nestlé, Little Steps is a good source of vitamins A, C, B2, and B12, iron, iodine and omega-3, and omega-6. The drink also contains calcium and vitamin D.
Vicky Woods, SMA Nutrition managing director, noted that consumers are increasingly choosing plant-based milk alternatives for themselves and as nutrient-packed options for their toddlers.
The new product is a ready-to-drink liquid that is packaged in resealable cartons for portability. Tesco and Asda carry a 200 ml pack. A 1-liter pack will be available at Asda.


Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
China Manufacturing PMI Rebounds in December, Offering Boost to Economic Growth Outlook
European Markets Mixed as Pound Weakens and Major Corporate Deals Emerge
U.S. Dollar Slides Toward Biggest Annual Loss Since 2017 as 2026 Risks Loom
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Gold Prices Rebound in Europe as Geopolitical Tensions and Fed Outlook Support Bullion
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
U.S. Dollar Steadies Ahead of Fed Minutes as Markets Eye Policy Divisions
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
U.S. Stock Futures Slip as Year-End Trading Turns Cautious
European Defense Stocks Slide as Trump Signals Progress in Ukraine-Russia Peace Talks 



